Document is current
Any future updates will be listed below
-
Authors
Desai, Rishi J.
Weberpals, Janick
Pillai, Haritha
Ajao, Adebola
Desibhatla, Mukund
Hawrusik, Rebecca
Hernández-Muñoz, José J.
Jones, Chanelle
Jones, Jamal T.
Lii, Joyce
Li, Jie
Lyons, Jennifer G.
Schoeplein, Ryan
Shebl, Fatma M.
Toh, Sengwee
Patorno, Elisabetta
Schneeweiss, Sebastian
-
Funding
Funding for this research was provided by:
U.S. Food and Drug Administration
- License Information
-
More Information
Article History
Received: 2 May 2025
Accepted: 30 November 2025
First Online: 15 December 2025
Competing interests
: Dr. Desai reports serving as Principal Investigator on investigator-initiated grants to the Brigham and Women’s Hospital from Novartis, Vertex, and Bayer on unrelated projects. Dr. Schneeweiss is co-principal investigator of an investigator-initiated grant to the Brigham and Women’s Hospital from Boehringer Ingelheim unrelated to the topic of this study. He is a consultant to Aetion Inc., a software manufacturer of which he owns equity. His interests were declared, reviewed, and approved by the Brigham and Women’s Hospital and MGB HealthCare System in accordance with their institutional compliance policies. Dr. Weberpals is now an employee of AstraZeneca and owns stocks in AstraZeneca. Other authors declare no financial or non-financial competing interests.
